Consequently, increased utilization of SGLT2 inhibitors, finerenone, and intravenous iron supplementation among appropriately selected patients may enhance symptom management and reduce the incidence of heart failure hospitalizations within the Polish population. The gene discussed is SLC5A2; the disease is heart failure.